PI3Kα-IN-8

Cat. No.:	HY-147983
CAS No.:	2315320-24-0
Molecular Formula:	$C_{26}H_{27}BrN_4O_2$
Molecular Weight:	507.42
Target:	PI3K; Reactive Oxygen Species; Apoptosis
Pathway:	PI3K/Akt/mTOR; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PI3Kα-IN-8 (Compound 9g) is a selective PI3Kα inhibitor with an IC_{50} of 0.012 μM. PI3Kα-IN-8 increases intracellular reactive oxygen species level, decreases mitochondrial membrane potential and induces apoptosis[1].			
IC_{50} & Target	PI3Kα 0.012 μM (IC_{50})	PI3Kδ 0.11 μM (IC_{50})	PI3Kγ 0.18 μM (IC_{50})	PI3Kβ 0.21 μM (IC_{50})
In Vitro	PI3Kα-IN-8 (Compound 9g) exhibits anticancer activity with IC_{50} values of 0.18 ± 0.03, 0.43 ± 0.05, 0.71 ± 0.08 and 0.63 ± 0.09 μM against HCT-116, MCF-7, HeLa and HepG2 cells, respectively[1]. PI3Kα-IN-8 upregulates Bax and cleaved caspase-3/9 levels, and downregulates Bcl-2 level[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

REFERENCES

[1]. Yang YQ, et al. Synthesis and anticancer evaluation of novel 1H-benzo[d]imidazole derivatives of dehydroabietic acid as PI3Kα inhibitors. Bioorg Chem. 2020 Jul;100:103845.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA